Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease
- Evelin L. SchaefferAffiliated withLaboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo Email author
- , Orestes V. ForlenzaAffiliated withLaboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo
- , Wagner F. GattazAffiliated withLaboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Alzheimer disease (AD) is the leading cause of dementia in the elderly and has no known cure. Evidence suggests that reduced activity of specific subtypes of intracellular phospholipases A2 (cPLA2 and iPLA2) is an early event in AD and may contribute to memory impairment and neuropathology in the disease.
The objective of this study was to review the literature focusing on the therapeutic role of PLA2 stimulation by cognitive training and positive modulators, or of supplementation with arachidonic acid (PLA2 product) in facilitating memory function and synaptic transmission and plasticity in either research animals or human subjects.
MEDLINE database was searched (no date restrictions) for published articles using the keywords Alzheimer disease (mild, moderate, severe), mild cognitive impairment, healthy elderly, rats, mice, phospholipase A2, phospholipid metabolism, phosphatidylcholine, arachidonic acid, cognitive training, learning, memory, long-term potentiation, protein kinases, dietary lipid compounds, cell proliferation, neurogenesis, and neuritogenesis. Reference lists of the identified articles were checked to select additional studies of interest.
Overall, the data suggest that PLA2 activation is induced in the healthy brain during learning and memory. Furthermore, learning seems to regulate endogenous neurogenesis, which has been observed in AD brains. Finally, PLA2 appears to be implicated in homeostatic processes related to neurite outgrowth and differentiation in both neurodevelopmental processes and response to neuronal injury.
The use of positive modulators of PLA2 (especially of cPLA2 and iPLA2) or supplementation with dietary lipid compounds (e.g., arachidonic acid) in combination with cognitive training could be a valuable therapeutic strategy for cognitive enhancement in early-stage AD.
KeywordsPhospholipase A2 Activation Learning Memory Cognitive training Therapeutic Alzheimer disease Mild cognitive impairment
- Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease
Volume 202, Issue 1-3 , pp 37-51
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Phospholipase A2
- Cognitive training
- Alzheimer disease
- Mild cognitive impairment
- Industry Sectors